DROPLETS, INC. v. E*TRADE BANK
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Dyk, O’Malley, and Wallach. Appeal from the PTAB.
Summary: A priority claim must be explicitly stated in the patent and cannot be incorporated by reference from an earlier patent.
E*Trade petitioned for IPR of Droplets’ ‘115 patent. The ‘115 patent specifically claimed priority only to the ‘838 patent. Droplets argued the ‘115 patent was entitled to the benefit of an earlier provisional application because the ‘115 patent incorporated by reference the ‘838 patent, which claimed priority to the provisional application. The Board held that incorporation by reference did not satisfy 35 U.S.C. § 120’s “specific reference” requirement to claim priority and invalidated all claims as obvious over the cited art. Droplets appealed.
Patent Office regulations require a priority claim under § 120 to recite the application number and familial relationship either in an application data sheet or in the first sentence of the specification. The Federal Circuit held that incorporating a different patent’s priority claim by reference did not meet those requirements. The Federal Circuit noted that § 120 should be applied strictly to prevent placing the burden of deciphering priority on the public when the patentee was in the best position to do so. Thus, the Federal Circuit affirmed.
This case is: DROPLETS, INC. v. E*TRADE BANK
Written by: Adam Powell and Alexander D. Zeng
Edited by: Paul Stewart
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…